Thomas M. MacDonald

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Disease
• Diabetes mellitus

His scientific interests lie mostly in Internal medicine, Cohort study, Surgery, Epidemiology and Endocrinology. His Internal medicine research incorporates themes from Diabetes mellitus and Cardiology. Thomas M. MacDonald combines subjects such as Relative risk, Clinical trial, Retrospective cohort study and Hazard ratio with his study of Cohort study.

His work deals with themes such as Meta-analysis, Lower risk, Poisson regression and Pioglitazone, which intersect with Surgery. The study incorporates disciplines such as Incidence and Etiology in addition to Epidemiology. His work in the fields of Endocrinology, such as Renin–angiotensin system, intersects with other areas such as Context.

His most cited work include:

• Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. (538 citations)
• Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (528 citations)
• Association of road-traffic accidents with benzodiazepine use (474 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of investigation include Internal medicine, Blood pressure, Cardiology, Surgery and Endocrinology. His work on Internal medicine is being expanded to include thematically relevant topics such as Diabetes mellitus. Thomas M. MacDonald has included themes like Ambulatory, Anesthesia and Placebo in his Blood pressure study.

His research in Surgery intersects with topics in Epidemiology and Myocardial infarction. In his work, Pediatrics is strongly intertwined with Incidence, which is a subfield of Epidemiology. His Cohort study research integrates issues from Proportional hazards model and Hazard ratio.

He most often published in these fields:

• Internal medicine (56.40%)
• Blood pressure (18.80%)
• Cardiology (17.40%)

What were the highlights of his more recent work (between 2014-2021)?

• Internal medicine (56.40%)
• Blood pressure (18.80%)
• Clinical trial (5.80%)

In recent papers he was focusing on the following fields of study:

Thomas M. MacDonald mainly investigates Internal medicine, Blood pressure, Clinical trial, Hazard ratio and Randomized controlled trial. His Internal medicine study which covers Cardiology that intersects with Uric acid. His Blood pressure research includes elements of Diabetes mellitus, Spironolactone, Placebo and Urology.

His study on Clinical trial also encompasses disciplines like

• Morning which intersects with area such as Physical therapy and Primary care,
• Dosing and related Pediatrics,
• Ambulatory blood pressure, Drug, Alternative medicine and Public health most often made with reference to Intensive care medicine. As a member of one scientific family, Thomas M. MacDonald mostly works in the field of Hazard ratio, focusing on Proportional hazards model and, on occasion, Clostridium difficile, Stool test, Campylobacter and Bacterial Gastroenteritis. His Randomized controlled trial research is multidisciplinary, incorporating perspectives in Amlodipine, Tolerability, Combination therapy and Prospective cohort study.

Between 2014 and 2021, his most popular works were:

• Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (528 citations)
• Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis (112 citations)
• Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies (81 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Disease
• Diabetes mellitus

Internal medicine, Blood pressure, Hazard ratio, Clinical endpoint and Spironolactone are his primary areas of study. Internal medicine is closely attributed to Cardiology in his research. His work is dedicated to discovering how Blood pressure, Urology are connected with Diuretic and Hydrochlorothiazide and other disciplines.

Within one scientific family, he focuses on topics pertaining to Proportional hazards model under Hazard ratio, and may sometimes address concerns connected to Dutasteride. His Clinical endpoint study also includes fields such as

• Myocardial infarction, Emergency medicine and Surgery most often made with reference to Stroke,
• Allopurinol that connect with fields like Risk factor, Febuxostat, Prospective cohort study, Gout and Record linkage. His biological study spans a wide range of topics, including Bisoprolol and Placebo, Crossover study.